<?xml version="1.0" ?><text author="Francesca Iannantuoni, Aranzazu M. de Marañon, Noelia Diaz-Morales, Rosa Falcon, Celia Bañuls, Zaida Abad-Jimenez, Victor  M. Victor, Antonio Hernandez-Mijares, Susana Rovira-Llopis" dateCollected="2019-11-03" id="autogum_academic_doc454" shortTile="sglt-inhibitor-empagliflozin" sourceURL="https://www.mdpi.com/2077-0383/8/11/1814/htm" speakerCount="0" speakerList="none" title="The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes" type="academic">
<head>
<s>
4
.
</s>
<s>
Discussion
</s>
</head>
<p>
<s>
iSGLT2s
are
a
new
class
of
oral
hypoglycaemic
drugs
that
block
glucose
reabsorption
at
the
renal
level
,
thus
promoting
urine
glucose
and
sodium
excretion
and
reducing
plasma
glucose
levels
.
</s>
<s>
In
the
present
study
,
we
have
focused
on
the
effects
of
empagliflozin
on
oxidative
stress
in
the
leukocytes
of
T2D
subjects
,
and
on
inflammatory
parameters
.
</s>
<s>
In
addition
to
a
reduction
in
body
weight
and
an
improved
metabolic
profile
—
characterized
by
reduced
plasma
glucose
and
HbA1c
levels
—
we
observed
a
reduction
in
mitochondrial
superoxide
production
in
diabetic
patients
after
treatment
with
the
iSGLT2
empagliflozin
,
together
with
increased
antioxidant
defenses
.
</s>
<s>
Moreover
,
reduced
proinflammatory
markers
and
increased
anti-inflammatory
parameters
were
maintained
after
24
weeks
of
treatment
with
empagliflozin
.
</s>
<s>
Besides
their
glucose-lowering
effect
,
iSGLT2s
produce
changes
in
the
lipid
profile
that
should
also
be
highlighted
.
</s>
<s>
Empagliflozin
treatment
is
correlated
with
increased
total
cholesterol
due
to
slight
increases
in
HDL-c
and
LDL-c
,
as
we
have
observed
,
and
reported
in
other
studies
.
</s>
<s>
However
,
there
is
a
well-documented
cardiovascular
protection
exerted
by
iSGLT2s
,
which
endows
these
drugs
with
clinical
potential
.
</s>
<s>
This
has
been
reflected
by
several
studies
,
such
as
the
EMPA-REG
OUTCOME
study
in
which
a
reduction
of
38
%
in
cardiovascular
mortality
was
evident
in
the
empagliflozin
vs.
placebo
group
.
</s>
<s>
However
,
neither
the
reduction
in
HbA1c
observed
in
the
study
(
0.60
%
over
12
weeks
)
nor
the
reduction
in
SBP
(
up
to
5
mmHg
)
are
sufficient
to
explain
the
reported
protection
against
cardiovascular
mortality
.
</s>
</p>
<p>
<s>
Interestingly
,
as
little
as
24
weeks
of
treatment
with
iSGLT2
is
sufficient
to
witness
their
beneficial
effects
on
HbA1c
,
body
weight
,
blood
pressure
and
,
most
importantly
,
on
the
cardiovascular
system
.
</s>
<s>
As
an
example
,
the
reduction
in
hospitalization
rates
for
heart
failure
in
the
group
treated
with
empagliflozin
in
the
EMPA-REG
OUTCOME
study
was
already
significant
at
this
time
point
.
</s>
<s>
A
recent
study
demonstrated
an
improved
arterial
stiffness
after
6
weeks
of
treatment
with
empagliflozin
in
T2D
patients
,
and
hs-CRP
was
shown
to
be
one
of
the
main
significant
determinants
for
this
improvement
.
</s>
<s>
Nevertheless
,
despite
the
available
evidence
,
the
molecular
mechanisms
underlying
the
cardiovascular
protection
attributable
to
iSGLT2
treatment
are
still
unknown
,
though
amelioration
of
oxidative
stress
has
been
hypothesized
to
be
a
potential
contributor
.
</s>
<s>
Because
cardiac
tissue
possesses
low
antioxidant
defenses
,
increasing
the
expression
or
activity
of
antioxidant
enzymes
could
be
a
mechanism
of
cardiac
protection
under
high
risk
situations
such
as
T2D
.
</s>
</p>
<p>
<s>
Oxidative
stress
occurs
when
the
production
of
pro-oxidant
species
overcomes
the
intrinsic
antioxidant
defense
system
of
the
cell
,
thus
triggering
damage
to
lipids
,
proteins
and
DNA
,
and
eventually
compromising
cellular
and
tissue
function
.
</s>
<s>
Exploring
the
role
of
SGLT2
inhibition
in
the
prevention
or
reduction
of
oxidative
stress
conditions
has
been
the
subject
of
several
studies
over
the
last
decade
.
</s>
<s>
However
,
to
date
,
most
of
the
studies
evaluating
the
effect
of
iSGLT2
on
oxidative
stress
have
been
performed
in
animal
models
.
</s>
</p>
<p>
<s>
Our
data
demonstrate
that
T2D
patients
receiving
iSGLT2
treatment
undergo
a
reduction
in
mitochondrial
superoxide
production
in
parallel
to
an
increase
in
glutathione
content
,
and
markedly
so
after
24
weeks
of
treatment
.
</s>
<s>
This
is
accompanied
by
increased
expression
of
the
antioxidant
enzymes
GSR
and
CAT
.
</s>
<s>
However
,
no
changes
in
plasma
protein
carbonyl
content
were
observed
with
empagliflozin
treatment
at
these
time-points
.
</s>
<s>
Whether
this
could
be
due
to
the
small
sample
size
or
would
require
long-term
empagliflozin
treatment
needs
to
be
addressed
in
future
research
.
</s>
<s>
Our
findings
are
in
accordance
with
previous
studies
in
rat
models
of
T2D
,
in
which
increased
antioxidant
enzyme
content
and
activity
in
renal
tissues
has
been
reported
.
</s>
<s>
Furthermore
,
iSGLT2
treatment
in
diabetic
mice
has
been
shown
to
induce
antioxidant
gene
expression
(
manganese-dependent
superoxide
dismutase
and
CAT
)
in
adipose
tissue
and
muscle
.
</s>
</p>
</text>